Emerging research suggest Retatrutide , a dual agonist targeting both incretin and another hormone, may offer a significant step forward for body treatment. Initial human trials have shown impressive losses in body tissue, possibly surpassing existing body composition therapies . Nevertheless , additional assessment is required to completely determ